Back to policy packages overview
This package demonstrates the impact of expanding access to novel pharmacological interventions aimed at reducing obesity. The effectiveness of GLP-1 agonists is revolutionary and such treatments are often viewed as the ‘silver bullet’ for solving the obesity crisis and saving the NHS. There is good evidence that people regain two-thirds of their weight when they stop taking the drug, and current guidelines only recommend a two-year course. This illustrative policy demonstrates that relying on treatment alone would be less effective than a package of policies that combine both prevention and treatment. Furthermore, at a cost of £42 billion over five years, relying on treatment alone is a prohibitively expensive solution.